Zacks Research Brokers Boost Earnings Estimates for Revvity

Revvity, Inc. (NYSE:RVTY) – Investment analysts at Zacks Research raised their Q2 2025 earnings estimates for Revvity in a note issued to investors on Monday, November 25th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $1.28 per share for the quarter, up from their prior forecast of $1.27. The consensus estimate for Revvity’s current full-year earnings is $4.85 per share. Zacks Research also issued estimates for Revvity’s FY2025 earnings at $5.17 EPS, Q2 2026 earnings at $1.40 EPS and FY2026 earnings at $5.67 EPS.

Several other research analysts also recently issued reports on RVTY. Wells Fargo & Company assumed coverage on shares of Revvity in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $130.00 price target on the stock. Barclays reduced their target price on shares of Revvity from $140.00 to $135.00 and set an “overweight” rating on the stock in a research report on Monday, November 25th. Sanford C. Bernstein lowered their price target on shares of Revvity from $150.00 to $145.00 and set an “outperform” rating for the company in a report on Tuesday, November 5th. Leerink Partners upped their price objective on Revvity from $130.00 to $135.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Finally, Robert W. Baird increased their price objective on Revvity from $136.00 to $138.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Seven analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $131.73.

Revvity Trading Down 0.1 %

RVTY stock opened at $116.14 on Thursday. The business has a fifty day moving average price of $119.71 and a 200 day moving average price of $115.97. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.56 and a quick ratio of 2.97. The stock has a market capitalization of $14.13 billion, a price-to-earnings ratio of 56.11, a P/E/G ratio of 3.57 and a beta of 1.05. Revvity has a fifty-two week low of $87.58 and a fifty-two week high of $129.50.

Revvity (NYSE:RVTY) last posted its quarterly earnings data on Monday, November 4th. The company reported $1.28 earnings per share for the quarter, topping the consensus estimate of $1.13 by $0.15. The company had revenue of $684.10 million during the quarter, compared to analyst estimates of $679.66 million. Revvity had a net margin of 9.34% and a return on equity of 7.42%. The company’s revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the business posted $1.18 earnings per share.

Hedge Funds Weigh In On Revvity

Institutional investors and hedge funds have recently made changes to their positions in the company. Assenagon Asset Management S.A. increased its stake in Revvity by 3,171.3% during the 2nd quarter. Assenagon Asset Management S.A. now owns 87,180 shares of the company’s stock worth $9,142,000 after purchasing an additional 84,515 shares in the last quarter. DekaBank Deutsche Girozentrale increased its position in shares of Revvity by 27.8% during the first quarter. DekaBank Deutsche Girozentrale now owns 84,383 shares of the company’s stock worth $8,790,000 after acquiring an additional 18,367 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Revvity in the 1st quarter valued at about $1,214,000. Artemis Investment Management LLP raised its position in Revvity by 21.3% in the 2nd quarter. Artemis Investment Management LLP now owns 107,634 shares of the company’s stock valued at $11,287,000 after buying an additional 18,916 shares during the last quarter. Finally, Bretton Capital Management LLC bought a new position in shares of Revvity during the 3rd quarter worth approximately $1,405,000. Institutional investors and hedge funds own 86.65% of the company’s stock.

Insider Transactions at Revvity

In other Revvity news, insider Tajinder S. Vohra sold 2,153 shares of the stock in a transaction on Monday, October 7th. The shares were sold at an average price of $122.09, for a total value of $262,859.77. Following the sale, the insider now directly owns 23,960 shares in the company, valued at approximately $2,925,276.40. This trade represents a 8.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.60% of the company’s stock.

Revvity announced that its Board of Directors has approved a share buyback program on Monday, November 4th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the company to reacquire up to 6.5% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s leadership believes its stock is undervalued.

Revvity Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, February 7th. Shareholders of record on Friday, January 17th will be issued a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a yield of 0.24%. The ex-dividend date is Friday, January 17th. Revvity’s dividend payout ratio (DPR) is currently 13.53%.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.